Interesting new study on Afrezza published today

[robbmo]

Hi,

VDEX performed an internal 12-month study of Afrezza, and released it to the public today.  Here is the link:


www.seventhform.com/vdexdownloads/vdex-whitepaper-072817.pdf

[mytakeonit]

All I can say is ... I'm transferring $$$ into my account to load up before the Aug. 7th conference call.

[promann]

Nice reading !! Thanks VDex ! That Disclaimer is very important ! Always knew they were also share holders while promoting Afrezza but nobody can hold that against them because they can see all the benifits it has.
A lot of time and work went into writing this (white paper) I applaud all there effort and thank all who was responsible for this . The Question is who is going to see this letter? I hope that some how this hits national news .. I also hope that this gets to all the doctors that treat Diabeties .
Thank you VDex for your devotion with Afrezza you will succeed.

[nadathing]

I haven't made it through the entire paper, but it is impressive. Thank you for posting the link.

[liane]

I realize this is an observational study, but BRAVO!!! Very well done and much needed.

[mnholdem]

Excerpt:

As a result of our investigation, we are compelled to recommend a new treatment paradigm for diabetes. Old ideas die hard, especially in medicine. But, there is a point when the body of knowledge becomes so substantial that it can no longer be ignored. Nor can it ethically or morally be ignored when lives are at stake. As measured by HbA1c, diabetes is less effectively managed today than in years past. This is not acceptable, and treatment necessarily needs to change.

Clearly, a different approach to the treatment of diabetes is called for. The tried and true, the conventional, hasn’t worked. It is time for blunt, honest, clear-headed, and creative thinking about this problem. We hope this report stimulates discussion and contributes to a better solution.

---

Excellent use of the term "pocket pancreas". Also, the disclaimer states that, while some VDex employees are MannKind shareholders, they were neither compensated nor guided by MannKind in regards to the study and subsequent white paper.

[liane]

Afrezza First, Afrezza Instead, Afrezza Always

[Deleted]

"Smokers. We prescribed the product in smokers despite the contradication, we saw no difference in the tolerance of the product among these patients as compared to non-smokers. In fact, smokers tended to have less difficulty using the inhaler, probably as a result of their familiarity with inhaling on a cigarette"

I have recommended Afrezza to several smokers but because of the label warning they did not pursue Afrezza.

[mnholdem]

There are a few VERY important facts expressed in this study that I suspect very few physicians are even aware of.

1. Afrezza is the ONLY insulin (identical insulin to what the human body produces) that is a monomer. All other insulin and insulin analogs deliver insulin in its hexamer form, which the body cannot immediately use. It takes precious time for the human body to break down hexamer insulin/insulin analogs injected in fat tissue to into dimer and finally monomer insulin in the blood stream, which is the only molecular form the human body can utilize. Because Afrezza is the only insulin delivered as a monomer;

2. Afrezza is the ONLY insulin that duplicates the physiological signaling (aka first phase response) which informs the liver to shut down glucose production. 

3. Insulin as the FIRST therapy in treating pre diabetes can halt and even reverse the progression of the disease. Insulin's placement by the American Diabetes Association as a last choice in the Standard of Care is understandably because all injected insulin is dangerous. VDex testing clearly demonstrates that Afrezza is, by far, the safest insulin of all and doctors have little to fear from using Afrezza to aggressively treat diabetes. That CANNOT be said of injectable insulin. This study validates those more rigorous studies (which I have posted) that early insulin treatment can result in drug-free remission in nearly half the patients with early-stage diabetes.

This white paper is, in my opinion, one of the most important publications to have been released to the medical community since Afrezza was approved by the FDA, and not simply because the clinic has published a patient-tested titration protocol. I hope that it gets re-printed in all the major medical journals. It the hope of VDex that the study will spark renewed research by the academic community. It will be a long road, but I believe that Alfred Mann's vision of Afrezza becoming the first treatment in the Diabetes Standard of Care may be realized.

The study authors state what most of us know to be true. Afrezza is a major leap forward. Mann didn't fall trap to developing drugs that circumvent the dangers of tradition insulin and insulin analogs. He simply realized that the world needed a better insulin...and he delivered it to the world.

Afrezza will become Alfred Mann's enduring legacy that will eclipse his development of the insulin pump.

[liane]

mnholdem,

That's why I pinned the thread for a while

[sportsrancho]

Jul 29, 2017 7:29:30 GMT -5 @kastanes said:

"Smokers. We prescribed the product in smokers despite the contradication, we saw no difference in the tolerance of the product among these patients as compared to non-smokers. In fact, smokers tended to have less difficulty using the inhaler, probably as a result of their familiarity with inhaling on a cigarette"

I have recommended Afrezza to several smokers but because of the label warning they did not pursue Afrezza.

Very true, I have two T2 smoker friends on Afrezza. Off-label just like kids:-)

[cjm18]

Is this study powerful enough to convince a doctor to prescribe? The disclaimer screams bias.

Well done vdex.

[mango]

VDEX White Paper 

[sayhey24]

Whats the take away "Give me that little blue cartridge". Excellent paper and it replicates the findings which Al had and which many of us have been saying for years. The only change I would make to their protocol is current metoformin users should be taken off metformin day 1 on afrezza. It messes up the afrezza to liver signalling and provides a negative benefit for liver action to counter the low.

This paper may also explain "my guess" what VDex has been up to, a major venture capital raise as the paper was most likely used for this.

One observation is should all slightly pre-diabetics be put on afrezza immediately almost the approach which has been taken with generic lipatol? The 56 year old "non-diabetic" did not seem to be hit Bernteins 83 while fasting.

I suspect Mannkind has similiar internal papers which replicate VDex's finding. It would be nice if Mike would release those now for public review. In the mean time here is an oldie but goodie - Al starts talking afrezza at minute 33 but at around minute 26 says it will obsolete the pump.
www.youtube.com/watch?v=muBuxTqxmQo

[mnholdem]

This white paper should be forwarded to all 3rd party insurers immediately! They need to read this to better understand why Afrezza should be given Preferred coverage over injected insulin.